Current evidence of bulevirtide as monotherapy compared to combination treatment with pegylated interferon for hepatitis delta.

Ruiz-Cobo JC, Palom A, Riveiro-Barciela M, Buti M

Open source

DOI
10.1080/14787210.2025.2578787
Published
2025 Nov
Container
Expert review of anti-infective therapy
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14787210.2025.2578787,
  title = {Current evidence of bulevirtide as monotherapy compared to combination treatment with pegylated interferon for hepatitis delta.},
  author = {Ruiz-Cobo JC and Palom A and Riveiro-Barciela M and Buti M},
  year = {2025},
  journal = {Expert review of anti-infective therapy},
  doi = {10.1080/14787210.2025.2578787},
  url = {https://doi.org/10.1080/14787210.2025.2578787}
}

RIS

TY  - JOUR
TI  - Current evidence of bulevirtide as monotherapy compared to combination treatment with pegylated interferon for hepatitis delta.
AU  - Ruiz-Cobo JC
AU  - Palom A
AU  - Riveiro-Barciela M
AU  - Buti M
PY  - 2025
JO  - Expert review of anti-infective therapy
DO  - 10.1080/14787210.2025.2578787
UR  - https://doi.org/10.1080/14787210.2025.2578787
ER  - 

APA

JC, R., A, P., M, R., & M, B. (2025). Current evidence of bulevirtide as monotherapy compared to combination treatment with pegylated interferon for hepatitis delta.. Expert review of anti-infective therapy. https://doi.org/10.1080/14787210.2025.2578787

Source records